

**About Procter & Gamble Health Limited:**

Procter & Gamble Health Limited (formerly Merck Limited) is one of India’s largest VMS Companies manufacturing and marketing over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle and improved quality of life. The Company was set up in India as one of Merck’s Asian subsidiaries in 1967. It was also the first Merck Group Company to go public in the year 1981. Till 2018, the Company was operating in all businesses included in the pharmaceuticals and chemicals businesses in the country. On December 1, 2018, P&G successfully completed the acquisition of Merck’s Consumer Health business further to approval of all relevant regulatory authorities and the fulfilment of other customary closing conditions. Please visit [www.pghealthindia.com](http://www.pghealthindia.com) for the latest news and information about Procter & Gamble Health Limited and its brands.

**About Procter & Gamble:**

P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide.

**CONTACTS**

**Media Contacts - Procter & Gamble Health Limited:**

* Ruchita Mehra | mehra.r@pg.com, +91- 9820986056

**Investor Relations Contact:**

* Flavia Machado | machado.f.1@pg.com, +91- 9773121273

 **Procter & Gamble Health Limited Announces First Quarter Results**

*Sales from operations up by 17% for quarter ended March 31, 2019*

**Mumbai, May 10, 2019:** Procter & Gamble Health Limited (formerly Merck Limited) announced today its financial results for the quarter ended March 31, 2018. The company has recorded a total revenue of ₹249 crores, up 22.2% vs. year ago (Sales from operations up by 17%) driven by a strong performance across brands, growth in exports, higher interest income and improved execution.

The Profit After Tax (PAT) was ₹40.7 crores Vs ₹22.7 crores from continued operations, up versus year ago driven by high interest income and operational efficiencies.

**Milind Thatte, Managing Director, Procter & Gamble Health Limited** said, *“We have continued our solid growth trajectory, recording a robust 17% growth in this quarter. With a brand portfolio backed by science and trusted by doctors, pharmacists and consumers, and the best of Consumer Health capabilities and cultures, we are working towards creating a much stronger presence in India’s fast-growing Consumer Health industry.”*